S&P 500   4,282.37
DOW   33,762.76
QQQ   354.20
Will Nvidia Be the Lifeline Intel Desperately Needs?
The Graphite Shortage Story You're Not Being Told (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
The Graphite Shortage Story You're Not Being Told (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
The Graphite Shortage Story You're Not Being Told (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.20
Will Nvidia Be the Lifeline Intel Desperately Needs?
The Graphite Shortage Story You're Not Being Told (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
The Graphite Shortage Story You're Not Being Told (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
The Graphite Shortage Story You're Not Being Told (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.20
Will Nvidia Be the Lifeline Intel Desperately Needs?
The Graphite Shortage Story You're Not Being Told (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
The Graphite Shortage Story You're Not Being Told (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
The Graphite Shortage Story You're Not Being Told (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.20
Will Nvidia Be the Lifeline Intel Desperately Needs?
The Graphite Shortage Story You're Not Being Told (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
The Graphite Shortage Story You're Not Being Told (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
The Graphite Shortage Story You're Not Being Told (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:CTKB

Cytek Biosciences (CTKB) Earnings Date, Estimates & Call Transcripts

$8.07
-0.12 (-1.47%)
(As of 06/2/2023 06:55 PM ET)
Compare
Today's Range
$7.98
$8.36
50-Day Range
$6.69
$11.99
52-Week Range
$6.45
$16.05
Volume
605,500 shs
Average Volume
1.10 million shs
Market Capitalization
$1.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.33

Earnings Summary

Upcoming
Earnings Date
Aug. 9Estimated
Actual EPS
(Feb. 28)
$0.03 Beat By $0.01
Consensus EPS
(Feb. 28)
$0.02
Last Year's Q1 EPS
(2/23/2022)
$0.05
Skip Charts & View Estimated and Actual Earnings Data

CTKB Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CTKB Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Cytek Biosciences Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20231$0.01$0.01$0.01 
Q2 20231$0.01$0.01$0.01 
Q3 20231$0.02$0.02$0.02 
Q4 20231$0.02$0.02$0.02 
FY 20234$0.06$0.06 $0.06

CTKB Earnings Date and Information

Cytek Biosciences last posted its earnings data on February 28th, 2023. The reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.01. The company had revenue of $48.34 million for the quarter, compared to analyst estimates of $49.87 million. Cytek Biosciences has generated ($0.01) earnings per share over the last year (($0.01) diluted earnings per share). Earnings for Cytek Biosciences are expected to grow by 128.57% in the coming year, from $0.07 to $0.16 per share. Cytek Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 9th, 2023 based off prior year's report dates.

Cytek Biosciences Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/9/2023
(Estimated)
        
2/28/2023Q4 2022$0.02$0.03+$0.01$0.03$49.87 million$48.34 million
11/9/2022Q3 2022$0.02$0.01($0.01)$0.01$43.36 million$40.48 million
8/10/2022Q2$0.02$0.03+$0.01$41.34 million$40.16 million    
5/11/2022Q1 2022$0.01($0.02)($0.03)($0.02)$33.00 million$35.06 million    
2/23/2022Q4 2021$0.05+$0.05$0.10$38.89 million
11/8/20219/30/2021$0.02$0.02$34.38 million    












Cytek Biosciences Earnings - Frequently Asked Questions

When is Cytek Biosciences's earnings date?

Cytek Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 9th, 2023 based off last year's report dates. Learn more on CTKB's earnings history.

Did Cytek Biosciences beat their earnings estimates last quarter?

In the previous quarter, Cytek Biosciences (NASDAQ:CTKB) reported $0.03 earnings per share (EPS) to beat the analysts' consensus estimate of $0.02 by $0.01. Learn more on analysts' earnings estimate vs. CTKB's actual earnings.

How much revenue does Cytek Biosciences generate each year?

Cytek Biosciences (NASDAQ:CTKB) has a recorded annual revenue of $164.04 million.

How much profit does Cytek Biosciences generate each year?

Cytek Biosciences (NASDAQ:CTKB) has a recorded net income of $2.58 million. CTKB has generated -$0.01 earnings per share over the last four quarters.

What is Cytek Biosciences's EPS forecast for next year?

Cytek Biosciences's earnings are expected to grow from $0.07 per share to $0.16 per share in the next year, which is a 128.57% increase.

More Earnings Resources from MarketBeat

This page (NASDAQ:CTKB) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -